On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from ...

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) ...

The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it ...

Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.

Number 4: The FDA has granted approval for Shanghai Henlius Biotech’s trastuzumab biosimilar, Hercessi (trastuzumab-strf; HLX02), for the treatment of HER2-positive breast cancer. The approval marks ...

April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of ...

The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) for the treatment of HER2-positive breast ...

During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at ...

In an interview with Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy focuses on ...

Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that ...

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine ...

Formycon, a Germany-based biosimilar manufacturer, shared that its revenues for 2023 were 83% higher than in 2022, reaching a ...